Minal Padden-Modi

Clinical Oncology Research Fellow for STAMPEDE2, Fan of 🇪🇺, #nhs, #prostatecancer, passionate about kindness. Views are my own. (She/Her)

[UroToday.com @urotoday]

Accelerated 177Lu-PSMA-617 protocol tested in #STAMPEDE2. @minal_pm & @Prof_Nick_James join @zklaassen_md to discuss the STAMPEDE2 trial Arm P, exploring upfront accelerated lutetium-PSMA-617 for #mHSPC. This trial could reveal crucial insights into dosing, PSMA expression, and biomarkers, with key endpoints of rPFS and OS > https://t.co/KgHM7tSdg4

[UroToday.com @urotoday]

Meta-analysis evaluates #cardiovascular risks of AR inhibitors in #ProstateCancer. Omar El-Taji & @AshwinUrol discuss with @CaPsurvivorship highlighting the importance of CV screening and monitoring when initiating ARSI treatment. #WatchNow > https://t.co/DjwGCaMyhC @JAMAOnc

[UroToday.com @urotoday]

How can participant experience of quality-of-life research be improved in cancer research: Views of the patient and public involvement representatives from the #STAMPEDE2 #ProstateCancer trial. Author commentary from @minal_pm and @dr_hannah_rush. Details on UroToday > https://t.co/IlxK8dQ7cA

[Dr Kamal Thippu MD FRCR @KamalThippu]

📣Our new ⁦@BJR_Radiology⁩ paper illustrates the importance of creating optimal #SABR plan for lung cancer!

#radonc
#lcsm ⁦

⁦⁦@minal_pm⁩ ⁦⁦@gleesoi⁩ ⁦@CRUKCamRadNet⁩

Link to full paper 👉 https://t.co/pLTgTzAdgR

[Nick James @Prof_Nick_James]

Third #Stampede presentation by @Silke_Gillessen. Metformin has weak effect on OS with possible interaction with disease volume. Significant positive effects on metabolic outcomes @MRCCTU @ICR_London

[Zach Klaassen @zklaassen_md]

Tip: Ph 3 STAMPEDE2 Nira + AAP trial w/ HRR gene alteration #ESMO24 @urotoday @MRCCTU

✏️mHSPC, 1:1 to Nira + AAP (Arm N) vs SoC (Arm A)
✏️~ 680 pts, ~80 sites in 🇬🇧
✏️Prim EP: OS
✏️Key Sec EP: rPFS, FFS, PCSS, QoL, Tox

[UroToday.com @urotoday]

Radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone #mCRPC: First results of EORTC-GUCG 1333/ #PEACE-3. Presentation by @Silke_Gillessen. #ESMO24 written coverage by @RKSayyid > https://t.co/5RSbqvRmQf @myESMO

[UroToday.com @urotoday]

The #STAMPEDE2 SABR trial: A phase III, randomized, open-label trial in patients with newly diagnosed oligometastatic #ProstateCancer starting ADT. Presentation by @Hoda_Aty @ICR_London. #ESMO24 written coverage by @zklaassen_md @GACancerCenter > https://t.co/98hvm8gF8x @myESMO

[Zach Klaassen @zklaassen_md]

TiP - STAMPEDE2 177Lu-PSMA-617 Trial in new mHSPC @urotoday @MRCCTU #ESMO24

🎯 n=1,756
✏️1:1 to Arm A (SoC) vs Arm P (SoC + 177Lu-PSMA-617)
- 177Lu-PSMA-617: 7.4 GBq on day 1 & day 8, 3x 6-weekly cycles
✏️Co-Prim EP: rPFS, OS
✏️Sec EP: FFS, PCSS, QoL, safety, tox, compliance, cost-eff
✏️20 🇬🇧 sites; in 2025 -- 🇪🇺 expansion

[Minal Padden-Modi @minal_pm]

Delighted our article on the importance of quality of life research produced alongside our brilliant STAMPEDE2 patient reps has been published in European Urology Oncology Journal
@dr_hannah_rush @Hoda_Aty @BertrandTOMBAL @Prof_Nick_James

https://t.co/lfcbXzq6uz

[Michael Hofman @DrMHofman]

Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht

https://t.co/TeFVVo6c9E

[Minal Padden-Modi @minal_pm]

@ally_bally1 @implausibleblog I really like how he owned the claims and invited them to attend his coffee mornings. Agree @implausibleblog I think he keeps it honest and cordial. It’s a really refreshing and elegant approach.

[Minal Padden-Modi @minal_pm]

Highlighted to watch the LD political broadcast by @GeorgeOsborne @edballs on their podcast, political currency. It’s refreshing to watch a different kinder way of doing politics. Ed Davey seems like a genuinely nice man. And agree whoever wins, needs to support our social care.

[Ed Davey @EdwardJDavey]

Caring isn’t just my family's story, it is the story of millions, caring for each other, dealing with tough times, and keeping going with love.

Sharing our story hasn't been easy, but it's important. It's time to bring carers' experiences into the light.

[Nick James @Prof_Nick_James]

Very interesting data - risk of increase in CV events not restricted to abiraterone - is a class effect with AR targeting, over and above the known risks with ADT alone

[Minal Padden-Modi @minal_pm]

@RhonddaBryant Sorry to hear this Chris! By far one of my favourite politicians and I hope you can use this as motivation to support the people in the NHS and cancer research when you are better. Really amazing to see such honesty, passion and energy in your posts. It’s truly refreshing.

[Hoda Aty @Hoda_Aty]

🎙️Episode 4 with special guest @Silke_Gillessen discussing the STAMPEDE trial Metformin Comparison! @ICR_London @MRCCTU @royalmarsdenNHS @Prof_Nick_James @Hoda_Aty

[Ed Balls @edballs]

Spain - proper, proper Eurovision song .. loved it #Eurovision2024

[Nick James @Prof_Nick_James]

Big milestone for STAMPEDE2 - our first Site Initiation Visit @royalmarsdenNHS. Behind the scenes look at how we do these important projects @MRCCTU @ICR_London @TrialsTribsPod

[Trials & Tribulations | Oncology Trials Podcast @TrialsTribsPod]

Follow our new "Trials & Tribulations" podcast! We delve into the behind-the-scenes of running clinical trials! #STAMPEDE2 @Prof_Nick_James @Hoda_Aty. Big thanks to @gu_onc @declangmurphy @RenuEapen at @APCCC_Lugano for this incredible introduction video!

[Daniel E Spratt @DrSpratticus]

As long as the community, which often is medoncs discussing radiopharm, as ‘dose’ we are doomed to not make progress. Pains me this basic rad physics 101 terminology is not even known. Now nuc med, who 100% knows the difference, is saying ‘dose’ to over simplify, when they know it is ‘activity’.

End of the day this is ionizing radiotherapy and dose to tumor matters for cell kill. Giving same activity for someone with 2 bone Mets vs 100 bone Mets is giving very different doses to normal and tumor.

These are not simple drugs like ARPI or chemo. @US_FDA needs to have greater flexibility for more personalized activity and dosimetry.

I encourage @DrMHofman @thomashopemd Herrmann, Emmett, and others to force the clinical community to adapt to appropriate terminology so we can make progress. If the ordering providers of RLT can’t understand this difference they shouldn’t be giving it.